- Home
- NTRB vs GNTA Comparison
NTRB vs GNTA Comparison
Compare NTRB & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- GNTA
- Stock Information
- Founded
- NTRB 2016
- GNTA 2014
- Country
- NTRB United States
- GNTA Italy
- Employees
- NTRB N/A
- GNTA N/A
- Industry
- NTRB Industrial Specialties
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NTRB Health Care
- GNTA Health Care
- Exchange
- NTRB Nasdaq
- GNTA Nasdaq
- Market Cap
- NTRB 77.9M
- GNTA 67.4M
- IPO Year
- NTRB N/A
- GNTA 2021
- Fundamental
- Price
- NTRB $6.17
- GNTA $5.34
- Analyst Decision
- NTRB
- GNTA Strong Buy
- Analyst Count
- NTRB 0
- GNTA 1
- Target Price
- NTRB N/A
- GNTA $25.00
- AVG Volume (30 Days)
- NTRB 28.2K
- GNTA 28.4K
- Earning Date
- NTRB 12-11-2024
- GNTA 01-01-0001
- Dividend Yield
- NTRB N/A
- GNTA N/A
- EPS Growth
- NTRB N/A
- GNTA N/A
- EPS
- NTRB N/A
- GNTA N/A
- Revenue
- NTRB $1,803,816.00
- GNTA N/A
- Revenue This Year
- NTRB N/A
- GNTA N/A
- Revenue Next Year
- NTRB N/A
- GNTA N/A
- P/E Ratio
- NTRB N/A
- GNTA N/A
- Revenue Growth
- NTRB N/A
- GNTA N/A
- 52 Week Low
- NTRB $1.93
- GNTA $2.20
- 52 Week High
- NTRB $9.60
- GNTA $7.28
- Technical
- Relative Strength Index (RSI)
- NTRB 50.57
- GNTA 56.89
- Support Level
- NTRB $5.24
- GNTA $4.89
- Resistance Level
- NTRB $6.40
- GNTA $6.20
- Average True Range (ATR)
- NTRB 0.71
- GNTA 0.70
- MACD
- NTRB -0.12
- GNTA -0.06
- Stochastic Oscillator
- NTRB 33.23
- GNTA 37.32
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.